Multi-purpose silastic dual-lumen central venous catheters for both collection and transplantation of hematopoietic progenitor cells

Bone Marrow Transplantation

Volumn 25, Issue 7, 2000, Pages 779-785

  Lazarus, H M ^a,b   Trehan, S ^a,b   Miller, R ^b   Fox, R M ^b   Creger, Rj ^b   Raaf, Jh ^a,b,c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b Ireland Cancer Center   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

Central venous catheter; Cost analysis; Hematopoietic growth factors; Hematopoietic stem cell transplantation; Mobilization; Thrombosis

Indexed keywords

ANTIBIOTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SILASTIC; UROKINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTEREMIA; BLOOD CULTURE; CENTRAL VENOUS CATHETER; COST BENEFIT ANALYSIS; FEMALE; HEMATOPOIETIC STEM CELL; HEMODIALYSIS; HUMAN; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADIOLOGY; STEM CELL TRANSPLANTATION; THROMBUS; VASCULAR ACCESS;

EID: 0034031875     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702225     Document Type: Article

References (60)

1. Armitage JO. Bone marrow transplantation. New Engl J Med 1994; 330: 827-838.
2. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-2258.
3. Kessinger A. Is blood or bone marrow better? Stem Cells 1993; 11: 290-295.
4. Körbling M, Fliedner T. The evolution of clinical peripheral blood stem cell transplantation. Bone Marrow Transplant 1996; 17: 675-678.
5. Nademanee A, Sniecinski I, Schmidt GM et al. High dose therapy followed by autologous peripheral blood stem cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994; 12: 2176-2186.
6. Iacone A, Pierelli A, Quaglietta A et al. Survival after PBPC transplantation and comparison of engraftment speed with autologous and allogeneic marrow transplantation: results of a multicenter study. Int J Artif Organs 1993; 16 (S-5): 45-50.
7. Schmitz, N, Linch DC, Dreger P et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
8. Chao NJ, Schriber JR, Grimes K et al. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031-2035.
9. Ravagnani F, Siena S, Bregni M et al. Large-scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. Eur J Cancer 1990; 26: 562-564.
10. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
11. Hillyer CD. Large volume leukapheresis to maximize peripheral blood stem cell collection. J Hematother 1993; 2: 529-532.
12. Espinosa MTF, Fox R, Creger RJ, Lazarus HM. Microbiologic contamination of peripheral blood progenitor cells collected for hematopoietic cell transplantation. Transfusion 1996; 36: 789-793.
13. Schwella N, Zimmermann R, Heuft HG et al. Microbiologic contamination of peripheral blood stem cell autografts. Vox Sang 1994; 67: 32-35.
14. Schepers KG, Davis JM, Rowley SD. Incidence of bacterial contamination of bone marrow grafts. Prog Clin Biol Res 1992; 377: 379-384.
15. Raaf JH. Results from use of 826 vascular access devices in cancer patients. Cancer 1985; 55: 1312-1321.
16. Raaf JH. Administration of chemotherapeutic agents. Techniques and controversies. Support Care Cancer 1994; 2: 335-346.
17. Winter JN, Lazarus HM, Rademaker A et al. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 1996; 14: 277-286.
18. Molineaux G, Pojda Z, Hampson IN et al. Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood 1990; 76: 2153-2158.
19. Koc ON, Gerson SL, Cooper BW et al. High-dose cyclophosphamide (CTX) + G-CSF is a better progenitor cell mobilization regimen than G-CSF + GM-CSF when compared directly in the same patient in a randomized cross-over clinical trial. Blood 1998; 92 (Suppl. 1): 724a (Abstr. 2927).
20. + cell transplantation for patients with advanced lymphoma: effects of overnight storage on peripheral blood progenitor cell enrichment and engraftment. Bone Marrow Transplant 1998; 21: 337-343.
21. Stadtmauer E, Schenkein D, Miller K et al. GM-CSF mobilized peripheral blood progenitor cells (PSC) and GM-CSF post infusion after high-dose melphalan, cyclophosphamide and total body irradiation (TBI) for advanced relapsed multiple myeloma. Blood 1993; 82: 264a (Abstr. 1043).
22. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-110.
23. Cassileth PA, Andersen J, Lazarus HM et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol 1993; 11: 314-319.
24. Fields KK, Elfenbein GJ, Lazarus HM et al. Maximum tolerated doses of ifosfamide, carboplatin, and etoposide given over six days followed by autologous stem cell rescue: toxicity profile. J Clin Oncol 1995; 13: 323-332.
25. Lazarus HM, Crilley P, Ciobanu R et al. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. J Clin Oncol 1992; 10: 1682-1689.
26. Stellato TA, Gauderer MWL, Lazarus HM, Herzig RH. Percutaneous silastic catheter insertion in patients with thrombocytopenia. Cancer 1985; 56: 2691-2693.
27. Raaf JH. Two Broviac catheters for intensive long term support of patients with cancer. Surg Gynecol Obstet 1984; 158: 173-176.
28. Raaf JH, Heil D. Open insertion of right atrial catheters through the jugular veins. Surg Gvnecol Obstet 1993; 77: 295-298.
29. Lazarus HM, Creger RJ, Bloom AD, Shenk R. Percutaneous femoral central venous catheter placement in patients undergoing bone marrow transplantation. Surg Gynecol Obstet 1990; 170: 403-406.
30. Raaf JH. Vascular access, catheter technology, and infusion pumps. In: Moossa AR. Schimpff SC, Robson MC (eds). Comprehensive Textbook of Oncology, Williams & Wilkins: Baltimore, 1991, pp 583-589.
31. Hickman RO, Buckner CD, Clift RA et al. A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet 1979; 148: 871-875.
32. Broviac JW, Cole JJ, Scrihner BH. A silicone rubber atrial catheter for prolonged parenteral alimentation. Surg Gynecol Obstet 1973; 136: 602-606.
33. Kincaid EH, Davis PW, Chang MC et al. 'Blind' placement of long-term central venous access devices: report of 589 consecutive procedures. Am Surg 1999; 65: 520-524.
34. Wenzel RP, Edmond MB. The evolving technology of venous access. New Engl J Med 1999; 340: 48-50.
35. Leihundgut K, Muller C, Muller K et al. Tunneled, double lumen Broviac catheters are useful, efficient and safe in children undergoing peripheral blood progenitor cell harvesting and transplantation. Bone Marrow Transplant 1996; 17: 663-667.
36. Stephens LC, Haire WD, Schmit-Pokorny K et al. Granulocyte-macrophage colony-stimulating factor: high incidence of apheresis catheter thrombosis during peripheral stem cell collection. Bone Marrow Transplant 1993; 11: 51-54.
37. Haire WD, Edney JA, Landmark JD, Kessinger A. Thrombotic complications of subclavian apheresis catheters: prevention with heparin infusion. J Clin Apher 1990; 5: 188-191.
38. Alegre A, Requena MJ, Fernandez-Villalta MJ et al. Quinton-Mahurkar catheter as short-term central venous access for PBSC collection: single-center experience of 370 apheresis in 110 patients. Bone Marrow Transplant 1996; 18: 865-869.
39. Goldberg SL, Mangan KF, Klump TR et al. Complications of peripheral blood stem cell harvesting: review of 554 PBSC leukaphereses. J Hematother 1995; 4: 85-90.
40. Meisenberg BR, Callaghan M, Sloan C et al. Complications associated with central venous catheters used for the collection of peripheral blood progenitor cells to support high-dose chemotherapy and autologous stem cell rescue. Support Care Cancer 1997; 5: 223-227.
41. Thompson L. Central venous catheters for apheresis access. J Clin Apher 1992; 7: 154-157.
42. Volkow P, Tellez O, Vazquez C et al. A single, double lumen high-flow catheter for patients undergoing peripheral blood stem cell transplantation. Experience at the National Cancer Institute in Mexico. Bone Marrow Transplant 1997; 20: 779-783.
43. Barzaghi A, Dell'Orto M, Rovelli A et al. Central venous catheter clots: incidence, clinical significance and catheter care in patients with hematologic malignancies. Ped Hematol Oncol 1995; 12: 243-250.
44. Newman KA, Reed WP, Schimpff SC et al. Hickman catheters in association with intensive cancer chemotherapy. Support Care Cancer 1993; 1: 92-97.
45. Ray S, Stacey R, Imrie M, Filshie J. A review of 560 Hickman catheter insertions. Anesthesia 1996; 51: 981-985.
46. Köksoy C, Kuzu A, Erden I, Akkaya A. The risk factors in central venous catheter-related thrombosis. Aust NZ J Surg 1995; 65: 796-798.
47. Biagi E, Arrigo C, Dell'Orto MG et al. Mechanical and infective central venous catheter-related complications: a prospective non-randomized study using Hickman and Groshong catheters in children with hematological malignancies. Support Care Cancer 1997; 5: 228-233.
48. Nightingale CE, Norman A, Cunningham D et al. A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy. Eur J Cancer 1997; 33: 398-403.
49. Hahn U, Goldschmidt H, Salwender H et al. Large-bore central venous catheters for the collection of peripheral blood stem cells. J Clin Apher 1995; 10: 12-16.
50. Reik RA, Noto TA, Fernandez HF. Safety of large-volume leukapheresis for collection of peripheral blood progenitor cells. J Clin Apher 1997; 12: 10-13.
51. Madero L, Díaz, MA, Benito A et al. Non-tunneled catheters for the collection and transplantation of peripheral blood stem cells in children. Bone Marrow Transplant 1997; 20: 53-56.
52. Madero L, Ruano D, Villa M et al. Non-tunneled catheters in children undergoing bone marrow transplantation. Bone Marrow Transplant 1996; 17: 87-89.
53. Haire WD, Lieberman RP, Lund GB et al. Thrombotic complications of silicone rubber catheters during autologous marrow and peripheral stem cell transplantation: prospective comparison of Hickman and Groshong catheters. Bone Marrow Transplant 1991; 7: 57-59.
54. Conlan MG, Haire WD, Lieberman RP et al. Catheter-related thrombosis in patients with refractory lymphoma undergoing autologous stem cell transplantation. Bone Marrow Transplant 1991; 7: 235-240.
55. Uderzo C, D'Angelo P, Rizzari C et al. Central venous catheter-related complications after bone marrow transplantation in children with hematological malignancies. Bone Marrow Transplant 1992; 9: 113-117.
56. Moosa HH, Julian TB, Rosenfeld CS, Shadduck RK. Complications of indwelling central venous catheters in bone marrow transplant recipients. Surg Gynecol Obstet 1991; 172: 275-279.
57. Darouiche RO, Raad ID, Heard SO et al. A comparison of two antimicrobial impregnated central venous catheters. New Engl J Med 1999; 340: 1-8.
58. Maki DG, Stolz SM, Wheeler S et al. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. Ann Intent Med 1997; 128: 257-266.
59. Raad I, Darouiche R, Dupuis J et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med 1997; 127: 267-274.
60. Home MK, Mayo DJ. Low-dose urokinase infusions to treat fibrinous obstruction of venous access devices in cancer patients. J Clin Oncol 1997; 15: 2709-2714.